- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.10. | Medicus Pharma Ltd: Medicus Pharma Highlights Three Years of Progress and Outlines Potential Path to Long Term Value | 216 | GlobeNewswire (Europe) | PHILADELPHIA, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided, biotech/life sciences company focused on advancing novel and potentially... ► Artikel lesen | |
| 08.10. | Medicus Pharma (MDCX) Shares Fall 24% After Hours: Here's Why | 8 | Benzinga.com | ||
| 07.10. | Medicus Pharma Ltd. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.09. | Medicus Pharma beantragt optimiertes Zulassungsverfahren für Teverelix | 4 | Investing.com Deutsch | ||
| MEDICUS PHARMA Aktie jetzt für 0€ handeln | |||||
| 29.09. | Medicus Pharma Ltd: Medicus Pharma Submits Optimized Teverelix Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer | 245 | GlobeNewswire (Europe) | PHILADELPHIA, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided, biotech/life sciences company focused on advancing novel and potentially... ► Artikel lesen | |
| 21.09. | Medicus Pharma to focus SkinJect development on Gorlin syndrome | 2 | Investing.com | ||
| 21.09. | Medicus Pharma fokussiert SkinJect-Entwicklung auf Gorlin-Syndrom | 6 | Investing.com Deutsch | ||
| 21.09. | Medicus Pharma Optimizes Portfolio Strategy With High-Value Focus | 1 | Benzinga.com | ||
| 21.09. | Medicus Pharma Ltd: Medicus Pharma Announces Exclusive Development Focus for SkinJect in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment | 248 | GlobeNewswire (Europe) | PHILADELPHIA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided, biotech/life sciences company focused on advancing novel and potentially... ► Artikel lesen | |
| 11.09. | Medicus Pharma Ltd. - 8-K, Current Report | 3 | SEC Filings | ||
| 10.09. | Medicus Pharma posts phase 2 study results for skin cancer drug | 2 | Investing.com | ||
| 10.09. | Medicus Pharma Ltd: Medicus Pharma Publishes Abridged Final Phase 2 SkinJect Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose | 2 | GlobeNewswire (USA) | ||
| 08.09. | Medicus Pharma shifts focus to precision oncology with CD228V | 3 | Investing.com | ||
| 08.09. | Medicus Pharma Ltd: Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company | 270 | GlobeNewswire (Europe) | PHILADELPHIA, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision-guided biotech/life sciences company focused on advancing the clinical... ► Artikel lesen | |
| 03.09. | Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion | 13 | Benzinga.com | ||
| 03.09. | Pfizer offloads scrapped Seagen ADC to Medicus Pharma in up to $1B+ deal | 33 | FierceBiotech | ||
| 03.09. | Medicus Pharma Ltd. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.08. | Medicus Pharma GAAP EPS of -$0.21 | 5 | Seeking Alpha | ||
| 13.08. | Medicus Pharma Ltd: Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update | 796 | ACCESS Newswire | Company Highlights Significant Regulatory, Clinical and Strategic Progress Across SkinJect and Teverelix Programs and a Strengthened Financial Position Supporting Continued Pipeline Execution and Expansion... ► Artikel lesen | |
| 12.08. | Medicus Pharma Ltd. - 10-Q, Quarterly Report | 2 | SEC Filings |
1 2 3 4 Weiter >>
77 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 26,235 | -0,06 % | Community Rückblick: wO-User zum Kurssturz bei Newron Pharma: "Der Wirkstoff ist - Stand jetzt - tot" | © Foto: Newron Pharmaceuticals SpAFDA-Schock bei Newron Pharma: Nach dem Kurssturz entbrennt im wO-Forum eine hitzige Debatte über Todesfälle, Managementkommunikation und die Zukunft des Hoffnungsträgers... ► Artikel lesen | |
| GILEAD SCIENCES | 139,24 | -0,83 % | Gilead and Vir forge $1.9bn pact to develop next-gen T-cell engagers | ||
| ELI LILLY | 1.122,20 | +0,50 % | 51,6 Millionen Schmerzpatienten: Warum Vertex, Eli Lilly und NeuroThera nach Alternativen zu Opioiden suchen | ||
| VERTEX PHARMACEUTICALS | 447,05 | -1,51 % | Forget Cystic Fibrosis: Vertex's Next Growth Engine Could Be Hormone Disorders | ||
| EYEPOINT | 2,700 | -4,26 % | XFRA PV3B: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 256,00 | -3,76 % | Ligand Pharmaceuticals: Ligand to Report Third Quarter 2026 Financial Results on October 29, 2026 | ||
| JAZZ PHARMACEUTICALS | 187,00 | -2,25 % | Jazz Pharmaceuticals plc - 8-K, Current Report | ||
| ACHIEVE LIFE SCIENCES | 5,600 | -10,40 % | Achieve Life Sciences Appoints Kaitlyn Tuson as Senior Vice President, Marketing and Communications | SEATTLE and VANCOUVER, British Columbia, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve and the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused... ► Artikel lesen | |
| UNITED THERAPEUTICS | 482,90 | -0,04 % | Liquidia Settles All Litigation With United Therapeutics; Shares Rise | WASHINGTON (dpa-AFX) - Liquidia Corp. (LQDA), a biopharmaceutical company, announced that it has entered into a global settlement agreement with United Therapeutics Corp. (UTHR) resolving all... ► Artikel lesen | |
| OPKO HEALTH | 1,460 | +1,39 % | Labcorp To Acquire BioReference Health Assets; OPKO Shares Rise 7.35% | WASHINGTON (dpa-AFX) - Labcorp Holdings Inc. (LH), a provider of innovative and comprehensive laboratory services, on Thursday announced that it had agreed to acquire select assets of BioReference... ► Artikel lesen | |
| ROYALTY PHARMA | 52,57 | -1,11 % | Royalty Pharma declares $0.235 dividend | ||
| CATALYST PHARMACEUTICALS | 27,300 | +2,63 % | Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals | The Italian pharma company grows its presence in the U.S. market and strengthens its global leadership in Brain Health and Rare DiseasesCompletion of the transaction gives Angelini Pharma ownership... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 59,95 | +0,17 % | BridgeBio Pharma, Inc.: BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | ||
| TG THERAPEUTICS | 48,800 | -2,20 % | TGTX Stock Rises 60% in 6 Months: Here's What You Should Know | ||
| CORBUS PHARMACEUTICALS | 3,986 | +3,37 % | Corbus Pharmaceuticals Holdings, Inc. - 8-K, Current Report |
MEDICUS PHARMA LTD gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von +0,060 (+1,68 %) liegt der Kurs bei 3,390 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEDICUS PHARMA LTD finden Sie auf Wallstreet Online.